ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
75.14
-0.40 (-0.53%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close75.54
Open75.11
Bid75.14 x 3100
Ask82.00 x 800
Day's Range74.66 - 75.47
52 Week Range56.81 - 75.57
Volume5,607,025
Avg. Volume6,880,068
Market Cap131.971B
Beta (3Y Monthly)0.87
PE Ratio (TTM)56.54
EPS (TTM)1.33
Earnings DateApr 16, 2019 - Apr 22, 2019
Forward Dividend & Yield1.28 (1.71%)
Ex-Dividend Date2019-01-14
1y Target Est80.08
Trade prices are not sourced from all markets
  • Final Trades: Abbott Labs, Gilead, Equinix & CVS
    CNBC Videos3 days ago

    Final Trades: Abbott Labs, Gilead, Equinix & CVS

    ABT, GILD, CVS, FINAL TRADES

  • Abbott (ABT) Dips More Than Broader Markets: What You Should Know
    Zacks11 hours ago

    Abbott (ABT) Dips More Than Broader Markets: What You Should Know

    Abbott (ABT) closed at $75.14 in the latest trading session, marking a -0.53% move from the prior day.

  • Here Are the Key Growth Catalysts for Abbott Laboratories in 2019
    Market Realist18 hours ago

    Here Are the Key Growth Catalysts for Abbott Laboratories in 2019

    How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Revenue and EPS growth trajectoryIn its fourth-quarter earnings press release, Abbott Laboratories (ABT) reported worldwide sales of $30.6 billion in fiscal 2018, a YoY

  • PR Newswire19 hours ago

    New Real-World Evidence Analysis of Nearly Half a Million FreeStyle® Libre System Users Shows Higher Rates of Scanning Improves Glucose Control

    - Data presented at ATTD confirms previous analyses that higher rates of scanning with the FreeStyle Libre system are strongly associated with improved glucose control - Prolonged hypoglycemia reduced ...

  • Medidata's (MDSO) Margins Under Pressure, Competition Rife
    Zacks19 hours ago

    Medidata's (MDSO) Margins Under Pressure, Competition Rife

    Medidata (MDSO) suffers from cutthroat competition in the clinical trial solutions market at the moment.

  • Will Boston Scientific or Abbott Report Higher Margins?
    Market Realist20 hours ago

    Will Boston Scientific or Abbott Report Higher Margins?

    How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Margin guidanceIn the company’s fourth-quarter earnings conference call, Boston Scientific (BSX) has guided for an adjusted gross margin of 72%–73% for fiscal 2018,

  • Boston Scientific or Abbott: Who Is Controlling Expenses Better?
    Market Realist21 hours ago

    Boston Scientific or Abbott: Who Is Controlling Expenses Better?

    How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Expense projections for fiscal 2019 In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) has guided for adjusted SG&A (selling, general, and

  • Boston Scientific or Abbott: A Look at Expected EPS Growth
    Market Realist2 days ago

    Boston Scientific or Abbott: A Look at Expected EPS Growth

    How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Earnings projections for fiscal 2019In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) has guided for adjusted EPS of $1.53–$1.58 for

  • CVS Health's (CVS) Q4 Earnings Top Estimates, Margins Up
    Zacks2 days ago

    CVS Health's (CVS) Q4 Earnings Top Estimates, Margins Up

    CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition holds immense promise.

  • Intuitive Surgical Gets FDA Nod for Ion Endoluminal System
    Zacks2 days ago

    Intuitive Surgical Gets FDA Nod for Ion Endoluminal System

    The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.

  • Boston Scientific or Abbott: Who Will Report More Revenue Growth?
    Market Realist2 days ago

    Boston Scientific or Abbott: Who Will Report More Revenue Growth?

    How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Revenue guidance for fiscal 2019In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) guided for YoY revenue growth of 7%–9%, YoY organic

  • PR Newswire2 days ago

    Abbott and Novo Nordisk Enter Partnership to Provide Integrated Digital Solution to People with Diabetes Using Insulin

    ABBOTT PARK, Ill. and BAGSVÆRD, Denmark, Feb. 20, 2019 /PRNewswire/ -- Abbott (ABT) and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLinkii mobile app and LibreViewiii cloud-based system). The partnership reflects both companies′ commitment to make diabetes management easier by connecting key technologies such as continuous glucose monitoring (CGM) and connected insulin pens.

  • What Analysts Recommend for Boston Scientific and Abbott
    Market Realist2 days ago

    What Analysts Recommend for Boston Scientific and Abbott

    How Boston Scientific and Abbott Laboratories Stack UpStock price movementsOn February 15, Boston Scientific (BSX) closed at $40.01, 0.23% higher than its previous closing price, 52.30% higher than its 52-week low of $26.27, and 0.79% below its

  • PR Newswire2 days ago

    Abbott Introduces the World's Most Sensitive Rapid Diagnostic Test, Determine™ HBsAg 2, to Accelerate Hepatitis B Care

    ABBOTT PARK, Ill., Feb. 20, 2019 /PRNewswire/ -- Abbott (ABT) announced today it has received CE Mark for the world's most sensitive rapid diagnostic test for the detection of hepatitis B surface antigen, the Determine™ HBsAg 2 test for use with serum, plasma or whole blood.1,2,3 This highly sensitive, easy-to-use, rapid lateral flow test enables identification of those with the virus and facilitates linkage to care in every healthcare setting.

  • TheStreet.com3 days ago

    Trading Notes for Select Stocks

    On a regular basis I make notes on all the stocks I've been trading. This allows me to stay focused on my overall thesis and to have a clear plan of action. I generally will have 50 or more names.

  • Medtronic (MDT) Beats on Q3 Earnings, Gross Margin Down
    Zacks3 days ago

    Medtronic (MDT) Beats on Q3 Earnings, Gross Margin Down

    Medtronic (MDT) demonstrates improved performances at CER based on growth in most of the business segments and all geographies.

  • Medtronic Posts Prelim PRODIGY Outcome on Opioid Overdose
    Zacks3 days ago

    Medtronic Posts Prelim PRODIGY Outcome on Opioid Overdose

    The favorable PRODIGY study result by Medtronic (MDT) is undoubtedly a timely, strategic finding.

  • Here's Why Investors Should Buy Surmodics (SRDX) Stock Now
    Zacks3 days ago

    Here's Why Investors Should Buy Surmodics (SRDX) Stock Now

    Surmodics' (SRDX) solid efforts to improve its research and development stature are likely to prove beneficial in the quarters ahead.

  • Align Technology Unveils iTero Element 5D Imaging System
    Zacks3 days ago

    Align Technology Unveils iTero Element 5D Imaging System

    Align Technology (ALGN) continues to expand work flow options of iTero scanners.

  • Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4
    Zacks4 days ago

    Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4

    Cryolife (CRY) revenues increase year over year across all geographies and major segments.

  • Markit4 days ago

    See what the IHS Markit Score report has to say about Abbott Laboratories.

    Abbott Laboratories NYSE:ABTView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ABT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABT. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ABT totaled $11.09 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. ABT credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock
    Zacks7 days ago

    Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock

    Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.

  • Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B
    Zacks8 days ago

    Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B

    Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.

  • Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down
    Zacks8 days ago

    Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down

    In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.

  • Baxter's Acute Therapies Profile Strong, Competition Rife
    Zacks8 days ago

    Baxter's Acute Therapies Profile Strong, Competition Rife

    Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.